Literature DB >> 14529834

Direct comparison of RD114-pseudotyped versus amphotropic-pseudotyped retroviral vectors for transduction of rhesus macaque long-term repopulating cells.

Jiong Hu1, Patrick Kelly, Aylin Bonifacino, Brian Agricola, Robert Donahue, Elio Vanin, Cynthia E Dunbar.   

Abstract

Recently, RD114 (feline endogenous retrovirus envelope protein)-pseudotyped retroviral particles have been shown to transduce human NOD/SCID repopulating cells efficiently. In this study, we compared directly transduction of repopulating cells with RD114-pseudotyped vector to that with standard amphotropic vector in the rhesus macaque model. G-CSF/SCF-mobilized CD34(+) rhesus peripheral blood cells were cultured in the presence of SCF, Flt-3 ligand, and MGDF on Retronectin-coated flasks. To assess directly the ability of the two pseudotypes to transduce primitive cells, both vectors were added simultaneously to the target cells every 24 h, for a total of four exposures in 96 h. The cells were reinfused after the animals received 1000 cGy total body irradiation. At the end of transduction, gene marking efficiency of CFU was higher with amphotropic LNL6 vector (mean 88.4%) vs RD114-G1Na vector (mean 18.5%). After long-term engraftment in three animals, total neo gene marking levels were 4-5% in PBMNCs and 1.5-4% in granulocytes. The RD114-G1Na marking levels were consistently higher in granulocytes than in mononuclear cells, while amphotropic LNL6 marking levels were higher in PBMNCs than in granulocytes. The differential gene marking patterns suggest that RD114 and amphotropic vectors may target distinct progenitor or stem cell populations. There was no clear advantage for RD114-pseudotyped vectors in this predictive preclinical model in terms of overall long-term marking levels; however, optimization of transduction conditions by increasing m.o.i. or inducing the receptor could potentially improve results with this novel vector system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14529834     DOI: 10.1016/s1525-0016(03)00239-9

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  5 in total

1.  Transduction of human primitive repopulating hematopoietic cells with lentiviral vectors pseudotyped with various envelope proteins.

Authors:  Yoon-Sang Kim; Matthew M Wielgosz; Phillip Hargrove; Steven Kepes; John Gray; Derek A Persons; Arthur W Nienhuis
Journal:  Mol Ther       Date:  2010-04-06       Impact factor: 11.454

2.  Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells.

Authors:  Grant D Trobridge; Robert A Wu; Michael Hansen; Christina Ironside; Korashon L Watts; Philip Olsen; Brian C Beard; Hans-Peter Kiem
Journal:  Mol Ther       Date:  2009-12-08       Impact factor: 11.454

3.  Improved transduction of human sheep repopulating cells by retrovirus vectors pseudotyped with feline leukemia virus type C or RD114 envelopes.

Authors:  M Lee Lucas; Nancy E Seidel; Christopher D Porada; John G Quigley; Stacie M Anderson; Harry L Malech; Janis L Abkowitz; Esmail D Zanjani; David M Bodine
Journal:  Blood       Date:  2005-03-17       Impact factor: 22.113

4.  Reconstitution of the myeloid and lymphoid compartments after the transplantation of autologous and genetically modified CD34+ bone marrow cells, following gamma irradiation in cynomolgus macaques.

Authors:  Sonia Derdouch; Wilfried Gay; Didier Nègre; Stéphane Prost; Mikael Le Dantec; Benoît Delache; Gwenaelle Auregan; Thibault Andrieu; Jean-Jacques Leplat; François-Loïc Cosset; Roger Le Grand
Journal:  Retrovirology       Date:  2008-06-19       Impact factor: 4.602

5.  Lentivector Producer Cell Lines with Stably Expressed Vesiculovirus Envelopes.

Authors:  Maha Tijani; Altar M Munis; Christopher Perry; Khaled Sanber; Marta Ferraresso; Tarit Mukhopadhyay; Michael Themis; Ilaria Nisoli; Giada Mattiuzzo; Mary K Collins; Yasuhiro Takeuchi
Journal:  Mol Ther Methods Clin Dev       Date:  2018-08-07       Impact factor: 6.698

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.